Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia

Fig. 4

SYK levels effect ARQ 531 potency. Immunoblot analysis for pMIT-Empty or SYK-TEL overexpressing Ba/F3-FLT3-ITD cell lines treated with increasing concentrations of ARQ 531 (representative of three independent blots). All cell lines were serum starved overnight followed by a 3-h treatment of 10 million cells. Twenty micrograms of total protein lysate was loaded per lane. GAPDH was used as loading control. Images are from same immunoblot but showing different exposure time optimum to each cell line (a). MTS proliferation assay for 72 h from three independent experiments using SYK overexpressing Ba/F3-FLT3-ITD cell lines. Parental Ba/F3-FLT3-ITD, Ba/F3 FLT3-ITD expressing pMIT-Empty, or pMIT-SYK-TEL were treated for 72 h with increasing concentrations of ARQ 531 (b), midostaurin (c), or gilteritinib (d)

Back to article page